Whitney & Co’s Atara Biotherapeutics ATRA Stock Holding History

Whitney & Co’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-2	Closed	-$2K	–	134
2018 Q3	$2K	Buy	+2	New	+$1.96K	﹤0.01%	450

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bridger Management New York $150M AUM 17.71% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Whitney & Co's ATRA Position: Q4 2018 in Review

Whitney & Co sold out of Atara Biotherapeutics (ATRA) in Q4 2018, closing a stake of 2 shares — an estimated $2K sold.

Whitney & Co first reported a position in ATRA in Q3 2018 and held it in 1 quarter. The position peaked at $2K in Q3 2018. 121 funds tracked by Wall St. Rank hold ATRA as of Q4 2018.

Whitney & Co reported no remaining Atara Biotherapeutics position as of Q4 2018 after selling out during the quarter.
Whitney & Co sold 2 Atara Biotherapeutics shares in Q4 2018, an estimated $2K.
Whitney & Co first reported a position in Atara Biotherapeutics in Q3 2018 and held it in 1 quarter.
Whitney & Co's Atara Biotherapeutics position peaked at $2K in Q3 2018.
121 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2018.

Based on Whitney & Co's 13F filing for Q4 2018, filed 7 Feb 2019.